A detailed history of Alpine Woods Capital Investors, LLC transactions in Crispr Therapeutics Ag stock. As of the latest transaction made, Alpine Woods Capital Investors, LLC holds 5,730 shares of CRSP stock, worth $238,310. This represents 0.04% of its overall portfolio holdings.

Number of Shares
5,730
Holding current value
$238,310
% of portfolio
0.04%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$44.62 - $62.75 $255,672 - $359,557
5,730 New
5,730 $269,000
Q1 2022

May 10, 2022

SELL
$53.19 - $79.24 $2.27 Million - $3.39 Million
-42,766 Closed
0 $0
Q4 2021

Feb 03, 2022

SELL
$70.09 - $111.29 $1.75 Million - $2.77 Million
-24,900 Reduced 36.8%
42,766 $3.24 Million
Q3 2021

Nov 12, 2021

BUY
$110.2 - $156.64 $15,317 - $21,772
139 Added 0.21%
67,666 $7.57 Million
Q2 2021

Aug 09, 2021

BUY
$100.84 - $161.89 $2.81 Million - $4.52 Million
27,899 Added 70.4%
67,527 $10.9 Million
Q1 2021

May 11, 2021

BUY
$110.72 - $210.04 $490,932 - $931,317
4,434 Added 12.6%
39,628 $4.83 Million
Q4 2020

Feb 01, 2021

BUY
$79.67 - $173.23 $548,607 - $1.19 Million
6,886 Added 24.33%
35,194 $5.39 Million
Q3 2020

Nov 02, 2020

BUY
$78.5 - $100.64 $256,067 - $328,287
3,262 Added 13.02%
28,308 $2.37 Million
Q2 2020

Aug 10, 2020

BUY
$38.5 - $76.05 $419,534 - $828,716
10,897 Added 77.02%
25,046 $1.84 Million
Q1 2020

May 04, 2020

BUY
$33.68 - $62.53 $136,067 - $252,621
4,040 Added 39.96%
14,149 $600,000
Q4 2019

Feb 07, 2020

SELL
$36.68 - $73.13 $1,797 - $3,583
-49 Reduced 0.48%
10,109 $616,000
Q4 2018

Feb 13, 2019

BUY
$22.73 - $42.34 $977 - $1,820
43 Added 0.43%
10,158 $290,000
Q3 2018

Nov 08, 2018

BUY
$44.35 - $65.71 $448,600 - $664,656
10,115 New
10,115 $449,000

Others Institutions Holding CRSP

About CRISPR Therapeutics AG


  • Ticker CRSP
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 78,009,296
  • Market Cap $3.24B
  • Description
  • CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....
More about CRSP
Track This Portfolio

Track Alpine Woods Capital Investors, LLC Portfolio

Follow Alpine Woods Capital Investors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Alpine Woods Capital Investors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Alpine Woods Capital Investors, LLC with notifications on news.